September 3, 2026 11:06 AM
The FDA approved Rasonque (daraxonrasib), a groundbreaking new drug to treat metastatic pancreatic cancer. A clinical trial found that those who received Rasonque had an average survival of about 13 months compared with just over 6 months with chemotherapy alone.